Skip to main content
Premium Trial:

Request an Annual Quote

KineMed, GSK Partner on Biomarker Discovery Deal

NEW YORK (GenomeWeb News) – KineMed today announced an agreement with GlaxoSmithKline for the use of KineMed's biomarker discovery platform in therapeutic areas of interest for the drug manufacturer.

The deal is aimed at the discovery, optimization, and validation of novel biomarkers for use in clinical trials directed at compounds for muscle wasting, fibrosis, and metabolic diseases. Marc Hellerstein, KineMed's chief of the scientific advisory board, said that reliable biomarkers that measure the therapeutic impact of drugs on the underlying disease processes are the missing links in developing drugs that target such diseases.

"KineMed's technology, which measures the dynamics of cellular biochemical networks, is focused on developing better metrics of the disease pathology of those disorders and therefore generates competitive advantage in developing effective drugs against them," he said in a statement.

Financial and other terms of the multiyear deal were not disclosed.

Based in Emeryville, Calif., KineMed discovers and develops biomarkers. It announced a deal with CHDI Foundation targeting Huntington's disease, and one with Pfizer to develop diabetes treatments, as GenomeWeb Daily News sister publication ProteoMonitor has reported.

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.